SEARCH

SEARCH BY CITATION

Keywords:

  • MRI contrast agent;
  • hydroxypyridinone (HOPO);
  • relaxivity;
  • 1,4,7-triazacyclononane (TACN);
  • terephthalamide (TAM);
  • dendrimer;
  • esteramide (EA) dendrimer;
  • drug delivery;
  • gadolinium

Commercial gadolinium magnetic resonance imaging (MRI) contrast agents are limited by low relaxivity (r1) and coordination to only a single water molecule (q = 1). Consequently, gram quantities of these agents must be injected to obtain sufficient diagnostic contrast. In this study, MRI contrast agents for T1 and T2 relaxivity were synthesized using hydroxypyridinone and terephthalamide chelators with mesityl and 1,4,7-triazacyclononane capping moieties. When covalently conjugated to a highly biocompatible esteramide dendrimer, T2 relaxation rates up to 52 m m−1 s−1 and T1 relaxation rates up to 31 m m−1 s−1 per gadolinium were observed under clinically relevant conditions. These values are believed to be brought about by using a dendritic macromolecule to decrease the molecular tumbling time of the small molecule complexes. These agents also show high aqueous solubility and low toxicity in vitro. In this study we report six new compounds: three discrete complexes and three dendrimer conjugates. Copyright © 2012 John Wiley & Sons, Ltd.